HSP2-THRIVE

HSP2-THRIVE

Among patients with atherosclerotic disease on statin therapy, does niacin+laropiprant reduce major vascular event when compared to placebo?

Study design: Multicenter, randomized, placebo-controlled trial

Population

• Number of patients studied: 25,673
• Inclusion criteria: Age 50-80 years, prior MI, CVD, PAD, or DM with symptomatic CAD
• Exclusion criteria: Liver disease, CKD, inflammatory muscle disease, prior adverse reaction to a study medication, active PUD, certain medications, recent MI, ACS, or stroke, planned revascularization, SOB, poor compliance, other significant medical comorbidities

Interventions

• Experimental group: Niacin extended-release 2g+laropiprant 40 mg PO daily
• Control group: Placebo

Primary outcome: Major vascular event (nonfatal MI, coronary mortality, stroke, arterial revascularization)

Conclusion

Among patients with atherosclerotic disease on statin therapy, niacin+laropiprant does not reduce incident major vascular events when compared to placebo. The therapy was poorly tolerated.

HPS2-THRIVE Collaborative Group. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. New England Journal of Medicine, 371(3), 203-212.